Cost-effectiveness of next-generation sequencing for advanced EGFR/ALK-negative non-small cell lung cancer. Kang DW, Park SK, Kang S, Lee EK, et al. Lung Cancer 2024;197:107970.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kang DW, Park SK, Kang S, Lee EK, et al. Cost-effectiveness of next-generation sequencing for advanced EGFR/ALK-negative non-small cell lung cancer. Lung Cancer 2024;197:107970.
PMID: 39366308